Citadel Advisors’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-21,700
| Closed | -$93.3K | – | 14690 |
|
|
2025
Q4 | $93.3K | Buy |
+21,700
| New | +$194K | ﹤0.01% | 11697 |
|
|
2024
Q3 | – | Sell |
-139
| Closed | -$1.29K | – | 15481 |
|
|
2024
Q2 | $1.29K | Buy |
+139
| New | +$3.32K | ﹤0.01% | 13839 |
|
|
2024
Q1 | – | Sell |
-533
| Closed | -$14.3K | – | 15602 |
|
|
2023
Q4 | $14.3K | Sell |
533
-214
| -29% | -$8.86K | ﹤0.01% | 12885 |
|
|
2023
Q3 | $45.2K | Sell |
747
-406
| -35% | -$38.1K | ﹤0.01% | 11863 |
|
|
2023
Q2 | $117K | Sell |
1,153
-669
| -37% | -$92.2K | ﹤0.01% | 10689 |
|
|
2023
Q1 | $322K | Buy |
1,822
+655
| +56% | +$219K | ﹤0.01% | 9231 |
|
|
2022
Q4 | $451K | Sell |
1,167
-177
| -13% | -$67.2K | ﹤0.01% | 8464 |
|
|
2022
Q3 | $453K | Buy |
1,344
+319
| +31% | +$116K | ﹤0.01% | 8678 |
|
|
2022
Q2 | $337K | Sell |
1,025
-614
| -37% | -$215K | ﹤0.01% | 9557 |
|
|
2022
Q1 | $717K | Sell |
1,639
-1,847
| -53% | -$758K | ﹤0.01% | 8509 |
|
|
2021
Q4 | $1.53M | Buy |
3,486
+1,436
| +70% | +$722K | ﹤0.01% | 6844 |
|
|
2021
Q3 | $1.14M | Buy |
2,050
+350
| +21% | +$176K | ﹤0.01% | 7818 |
|
|
2021
Q2 | $873K | Sell |
1,700
-2,125
| -56% | -$1.35M | ﹤0.01% | 8706 |
|
|
2021
Q1 | $2.99M | Sell |
3,825
-186
| -5% | -$127K | ﹤0.01% | 5457 |
|
|
2020
Q4 | $2.19M | Buy |
4,011
+1,089
| +37% | +$571K | ﹤0.01% | 5178 |
|
|
2020
Q3 | $1.34M | Buy |
2,922
+1,525
| +109% | +$886K | ﹤0.01% | 5487 |
|
|
2020
Q2 | $860K | Buy |
1,397
+203
| +17% | +$112K | ﹤0.01% | 6106 |
|
|
2020
Q1 | $568K | Sell |
1,194
-931
| -44% | -$506K | ﹤0.01% | 6254 |
|
|
2019
Q4 | $1.23M | Sell |
2,125
-136
| -6% | -$95.4K | ﹤0.01% | 5229 |
|
|
2019
Q3 | $1.49M | Sell |
2,261
-158
| -7% | -$131K | ﹤0.01% | 4944 |
|
|
2019
Q2 | $1.87M | Buy |
2,419
+769
| +47% | +$540K | ﹤0.01% | 4621 |
|
|
2019
Q1 | $1.17M | Buy |
1,650
+631
| +62% | +$378K | ﹤0.01% | 5323 |
|
|
2018
Q4 | $477K | Sell |
1,019
-1,150
| -53% | -$742K | ﹤0.01% | 6464 |
|
|
2018
Q3 | $1.87M | Buy |
2,169
+177
| +9% | +$128K | ﹤0.01% | 4537 |
|
|
2018
Q2 | $1.37M | Buy |
1,992
+1,145
| +135% | +$582K | ﹤0.01% | 4687 |
|
|
2018
Q1 | $378K | Sell |
847
-320
| -27% | -$155K | ﹤0.01% | 6365 |
|
|
2017
Q4 | $514K | Sell |
1,167
-427
| -27% | -$195K | ﹤0.01% | 5608 |
|
|
2017
Q3 | $786K | Buy |
1,594
+516
| +48% | +$258K | ﹤0.01% | 4652 |
|
|
2017
Q2 | $597K | Sell |
1,078
-1,230
| -53% | -$780K | ﹤0.01% | 4874 |
|
|
2017
Q1 | $1.53M | Buy |
2,308
+2,016
| +690% | +$1.08M | ﹤0.01% | 3402 |
|
|
2016
Q4 | $98K | Sell |
292
-252
| -46% | -$80.9K | ﹤0.01% | 6684 |
|
|
2016
Q3 | $164K | Buy |
+544
| New | +$118K | ﹤0.01% | 6422 |
|
|
2016
Q1 | – | Sell |
-25
| Closed | -$15K | – | 8154 |
|
|
2015
Q4 | $15K | Sell |
25
-72
| -74% | -$39.5K | ﹤0.01% | 8122 |
|
|
2015
Q3 | $50K | Buy |
+97
| New | +$64.9K | ﹤0.01% | 7587 |
|
Other funds holding TVRD
SPC
VCM
AFG
SAM
DWAM
Citadel Advisors's TVRD Position: Q3 2024 in Review
Citadel Advisors sold out of Tvardi Therapeutics (TVRD) in Q3 2024, closing a stake of 1,266 shares — an estimated $11.8K sold.
Citadel Advisors first reported a position in TVRD in Q3 2015 and held it in 32 quarters. The position peaked at $7.76M in Q3 2019. 69 funds tracked by Wall St. Rank hold TVRD as of Q3 2024.
- Citadel Advisors reported no remaining Tvardi Therapeutics position as of Q3 2024 after selling out during the quarter.
- Citadel Advisors sold 1,266 Tvardi Therapeutics shares in Q3 2024, an estimated $11.8K.
- Citadel Advisors first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 32 quarters.
- Citadel Advisors's Tvardi Therapeutics position peaked at $7.76M in Q3 2019.
- 69 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2024.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.